Pristine Surgical LLC in Manchester raised $18 million in its third appeal for investment capital. The funds will be used to increase the company's manufacturing capability, launch a new product and map out future expansion.
"We are grateful for the support of our new and existing investors who are eagerly anticipating the launch of our single-use platform," said Bryan Lord, Pristine CEO. "We will give hospitals and surgery centers the full confidence that their arthroscopic and laparoscopic procedures are performed with high-performance digital scopes, delivered in 100% sterile single-use kits, and at a reduced cost."
According to a statement, Pristine Surgical has developed a first-of-its-kind, single-use visualization platform for surgical and diagnostic rigid endoscopic procedures by combining state-of-the-art, high-definition digital imaging with advanced LED lighting, artificial intelligence, and cloud-based software.
Pristine's single-use arthroscopes and laparoscopes are delivered in a sterile kit, and together with its cloud-based workflow reduction software, it is expected to reduce costs and risks for more than 23 million procedures per year.
Headquartered in Manchester, Pristine's management team is guided by a seven-person board of directors and a 10-person medical advisory board.